Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement.
Patients who were willing and able to undergo bilateral ascending contrast venography
Either sex, any race, 18 years and older
You may not be if
Known or suspected bleeding or coagulation disorder in the patient or his or her first-degree relative
Known or suspected history of heparin-induced thrombocytopenia
Known coagulopathy
Active bleeding or at high risk for bleeding
Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
Active hepatobiliary disease
Alcohol and/or substance abuse within the past year
Any condition for which surgery or administration of an anticoagulant is contraindicated
Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg
Clinically significant laboratory abnormalities at the enrollment visit:
Hemoglobin \<10 g/dL
Platelet count \<100,000/mm\^3
Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault
Alanine aminotransferase or aspartate aminotransferase \>2\*upper limit of normal or a total bilirubin ≥ 1.5\*1 (unless an alternative causative factor such as Gilbert's syndrome was identified)
Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with mechanical valves, warfarin eligible atrial fibrillation)
Current use of dextrans or fibrinolytics
Treatment with medications affecting coagulation or platelet function
